RI

RIBOMIC Inc.

Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.

4591 | T

Overview

Corporate Details

ISIN(s):
JP3974850004
LEI:
Country:
Japan
Address:
港区白金台3−16−13 白金台ウスイビル6階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RIBOMIC Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics. The company utilizes its proprietary RiboART system, a unique platform technology, to generate first-in-class, molecularly targeted drugs using RNA aptamers. RIBOMIC's research and development pipeline focuses on addressing unmet medical needs in a range of therapeutic areas, including ophthalmic disorders, pain, fibrosis, bone diseases, and rare diseases. The company pursues its mission through internal drug development programs and strategic partnerships within the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 08:30
Registration Form
確認書
Japanese 8.0 KB
2025-11-12 08:30
Interim Report
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 261.6 KB
2025-07-23 08:45
Registration Form
有価証券届出書(組込方式)
Japanese 326.2 KB
2025-06-20 03:50
Registration Form
確認書
Japanese 7.9 KB
2025-06-20 03:49
Governance Information
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-20 03:43
Annual Report
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2024-11-13 02:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-11-13 02:13
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-06-26 04:47
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2024-06-26 04:45
Governance Information
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-26 04:44
Registration Form
確認書
Japanese 8.0 KB
2024-06-26 04:43
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 2.0 MB
2024-02-14 02:26
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-02-14 02:25
Quarterly Report
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 178.6 KB
2023-11-13 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all RIBOMIC Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RIBOMIC Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RIBOMIC Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

TechnoPro Holdings, Inc. Logo
Technology staffing and services group providing engineers and solutions for R&D and development.
Japan
6028
TechTarget, Inc. Logo
Provides purchase intent-driven marketing and sales services for B2B tech vendors.
United States of America
TTGT
Tenaya Therapeutics, Inc. Logo
Developing gene therapy, cellular regeneration & precision medicine for heart disease.
United States of America
TNYA
Terns Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing small-molecule drugs for oncology & metabolic diseases.
United States of America
TERN
A holding company active in property rentals and marine seismic & defense R&D.
Virgin Islands (British)
THAL
Holding company for real estate development, building management, and community-integrated hotels.
Japan
3271
The Lifestyle Group Logo
Developed luxury/well-being ventures & provided multimedia systems for franchise network growth.
Italy
TLSG
Theranexus Logo
A biopharma developing drugs for rare neurological diseases by targeting non-neuronal cells.
France
ALTHX
THE WHY HOW DO COMPANY, Inc. Logo
A corporate regeneration platform for business turnarounds, M&A, and succession solutions.
Japan
3823
Tiziana Life Sciences Ltd Logo
Biotech firm developing immunotherapies for neurodegenerative diseases like MS and Alzheimer's.
United States of America
TLSA

Talk to a Data Expert

Have a question? We'll get back to you promptly.